Evaluation of pharmacogenetic automated clinical decision support for clopidogrel.
Amanda MassmannJoel Van HeukelomMax WeaverApril SchultzDebbie M FigueroaAdam StysTomasz P StysKurt D ChristensenPublished in: Pharmacogenomics (2024)
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing. Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19 -clopidogrel CDS was deployed at a single healthcare system during 2015-2023. Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 ( p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001). Conclusion: CDS for CYP2C19 -clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.
Keyphrases
- acute coronary syndrome
- clinical decision support
- percutaneous coronary intervention
- antiplatelet therapy
- quantum dots
- electronic health record
- primary care
- adverse drug
- end stage renal disease
- randomized controlled trial
- ejection fraction
- coronary artery disease
- newly diagnosed
- machine learning
- chronic kidney disease
- emergency department
- peritoneal dialysis
- prognostic factors
- high throughput
- gene expression
- deep learning
- human health